Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 258-265

  Achhra, Amit C ^a   Phanuphak, Praphan ^b   Amin, Janaki ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

antiretroviral therapy; CD4+ cell count; cohort analysis; HIV; immunological; long term; low middle income countries; virological

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG RESPONSE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCOME; LOWEST INCOME GROUP; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 79959348084     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283476c72     Document Type: Review

References (86)

1. Lohse N, Hansen A-BE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
2. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51-59. (Pubitemid 351920404)
3. Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
4. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130. (Pubitemid 40347381)
5. Palella FJJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
6. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24:1877-1886.
7. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49:1109-1116.
8. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
9. + cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
10. World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. World Health Organization (WHO) 2003. http://www.who.int/hiv/pub/prev-care/en/ arvrevision2003en.pdf. [Accessed 16 March 2011]
11. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510. (Pubitemid 44142772)
12. The World Bank. World Bank list of economies. http://data.worldbank.org/ about/country-classifications/country-and-lending-groups#Low-income. [Accessed 16 March 2011]
13. Sabin CA, Phillips AN. Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrob Chemother 2001; 47:371-375. (Pubitemid 32303400)
14. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-287.
15. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-1915. (Pubitemid 37070276)
16. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-372. (Pubitemid 41022115)
17. Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190:1860-1868. (Pubitemid 39487833)
18. Le Moing V, Thiébaut R, Chêne G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med 2007; 8:156-163. (Pubitemid 46915686)
19. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-446. (Pubitemid 46147630)
20. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413. (Pubitemid 47176633)
21. Egger S, Petoumenos K, Kamarulzaman A, et al. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr 2009; 50:513-520. One of the few studies providing direct comparision between high-income and low-middle income country cohorts.
22. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192. (Pubitemid 46869811)
23. Mocroft A, Phillips AN, Ledergerber B, et al. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther 2010; 15:563-570.
24. Kaufmann GR, Elzi L, Weber R, et al. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 2011; 25:441-451.
25. Lok JJ, Bosch RJ, Benson CA, et al. Long-term increase in CD4+T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 2010; 24:1867-1876. This recent study provides 7-year data in those with relatively higher CD4+ cell counts (270/ml) at baseline, providing evidence for long-term benefits of earlier start of treatment.
26. + recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48:541-546.
27. Engsig FN, Gerstoft J, Kronborg G, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis 2010; 10:318.
28. Kelley Colleen F, Kitchen Christina MR, Hunt Peter W, et al. Incomplete peripheral cd4+ cell count restoration in HIV-infected patients receiving longterm antiretroviral treatment. Clin Infect Dis 2009; 48:787-794.
29. Pacheco YM, Jarrín I, Del Amo J, et al. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr HIV Res 2009; 7:612-619.
30. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-1559.
31. Kelly M, French M, Lewin S, et al. Antiretroviral therapy intensification with raltegravir or antilipopolysaccharide immunoglobulin from hyper-immune bovine colostrum in antiretroviral-treated patients exhibiting a suboptimal CD4+ T-cell response: The CORAL Study In: 22nd Annual conference of the Australasian Society for HIV Medicine; 22nd Oct, 2010, Sydney. Abstract 482.
32. Lampe FC, Smith CJ, Madge S, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167:692-700.
33. Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 2008; 13:927-936.
34. UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 2010; 50:1275-1285. This study, with over 8-years of follow-up, provides long-term probability of virological failure and detection of resistance mutations in those with relatively newer regimens.
35. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010; 55:460-465.
36. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One 2009; 4:e7196.
37. Ballif M, Ledergerber B, Battegay M, et al. Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE 2009; 4:e8275.
38. Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-termfollow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007; 370:1923-1928. (Pubitemid 350193334)
39. Lodwick R, Costagliola D, Reiss P, et al. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010; 170:410-419. This study presents data from a large collaboration with over 45 000 patients, providing long-term estimates of triple-class virological failure.
40. Greenbaum AH, Wilson LE, Keruly JC, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008; 22:2331-2339.
41. Weintrob AC, Fieberg AM, Agan BK, et al. Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr 2008; 49:40-47.
42. Cuzin L, Delpierre C, Gerard S, et al. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis 2007; 45:654-657. (Pubitemid 47328650)
43. Sobrino-Vegas P, Garcia-San Miguel L, Caro-Murillo AM, et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7:224-230.
44. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23:1881-1889. This study provides the long-term (over 7 years) data of well-characterized HIV/HBV coinfected population.
45. Peters L, Mocroft A, Soriano V, et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009; 50:457-463. This study provides the long-term data of well-characterized HIV/HCV coinfected population. One of the few studies providing immunological responses according to various HCV genotypes.
46. Smith C, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV drugs Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010; 24:1537-1548.
47. Palepu A, Tyndall M, Yip B, et al. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003; 32:522-526. (Pubitemid 36423124)
48. Weber R, Huber M, Rickenbach M, et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med 2009; 10:407-416. This study analyses and compares the response to ART between former IDUs, those in opiod substitution programs with or without current IDU and current IDUs.
49. Bannister WP, Ruiz L, Loveday C, et al. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006; 11:707-715. (Pubitemid 44497166)
50. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-1305.
51. Khanna N, Opravil M, Furrer H, et al. CD4+T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.[Erratum appears in Clin Infect Dis. 2009 May 15;48(10):1491]. Clin Infect Dis 2008; 47:1093-1101.
52. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291-2302.
53. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24:563-572. This study provides 5-7-year data from a primary care antiretroviral treatment program from rural South Africa.
54. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009; 151:241-251; W-252. The report is from a large national antiretroviral treatment program with over 45 000 patients in follow-up.
55. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
56. Toro PL, Katyal M, Carter RJ, et al. Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS 2010; 24:515-524.
57. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.
58. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22:2303-2311.
59. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678-687.
60. Wolff MJ, Cortes CP, Shepherd BE, Beltran CJ. Long-term outcomes of a national expanded access program to antiretroviral therapy: the Chilean AIDS cohort. J Acquir Immune Defic Syndr 2010; 55:368-374.
61. Barth R, Tempelman H, Moraba R, Hoepelman A. long-term outcome of an HIV-treatment programme in rural Africa: viral suppression despite early mortality. AIDS Research and Treatment, vol. 2011, Article ID 434375, 5 pp., 2011. doi:10.1155/2011/434375.
62. Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17. (Pubitemid 40094112)
63. Zhou J, Li PC, Kumarasamy N, et al. Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results fromthe TREAT Asia HIV Observational Database (TAHOD). HIV Med 2010; 11:31-39.
64. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
65. Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009; 14:1048-1058.
66. Keiser O, Anastos K, Schechter M, et al. Antiretroviral therapy in resourcelimited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870-879.
67. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. World Health Organization; Geneva 2010. http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. [Accessed 16 March 2011]
68. Boulle A, Ford N. Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Sex Transm Infect 2007; 83:503-505.
69. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010; 24:2263-2270.
70. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
71. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-567. (Pubitemid 351931216)
72. Ekouevi DK, Balestre E, Ba-Gomis FO, et al. Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health 2010; 15 (Suppl 1):34-42.
73. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010; 376:449-457.
74. Tassie JM, Baijal P, Vitoria MA, et al. Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr 2010; 54:437-441.
75. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 2010; 53:405-411.
76. Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4:e5790.
77. Egger M, Spycher BD, Sidle J, et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-saharan Africa. PLoS Med 2011; 8:e1000390.
78. Nakanjako D, Colebunders R, Coutinho AG, Kamya MR. Strategies to optimize HIV treatment outcomes in resource-limited settings. AIDS Rev 2009; 11:179-189.
79. Ford N, Darder M, Spelman T, et al. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS ONE 2010; 5:e10460.
80. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50:529-536.
81. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690. (Pubitemid 44200639)
82. Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav 2009; 13 (Suppl 1):82-91.
83. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 2010; 5:70-77.
84. World Health Organisation. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach. World Health Organization; Geneva: 2007. http://www.who.int/hiv/amds/Prioritizing2ndLineARVs-WHO.pdf. [Accessed 16 March 2011]
85. Srikantiah P, Ghidinelli M, Bachani D, et al. Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region. AIDS 2010; 24 (Suppl 3):S62-71. Data from Universal Access Report from United Nations on ART program indicators of nine LMICs (over 700 000 patients) in Asia-Pacific region.
86. + cell count at the time of switch to second-line treatment.